- Home
- CCM vs SNTI Comparison
CCM vs SNTI Comparison
Compare CCM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- SNTI
- Stock Information
- Founded
- CCM 1997
- SNTI 2016
- Country
- CCM China
- SNTI United States
- Employees
- CCM N/A
- SNTI N/A
- Industry
- CCM Medical/Nursing Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- SNTI Health Care
- Exchange
- CCM Nasdaq
- SNTI Nasdaq
- Market Cap
- CCM 33.3M
- SNTI 39.6M
- IPO Year
- CCM 2009
- SNTI N/A
- Fundamental
- Price
- CCM $5.64
- SNTI $1.30
- Analyst Decision
- CCM
- SNTI Strong Buy
- Analyst Count
- CCM 0
- SNTI 2
- Target Price
- CCM N/A
- SNTI $8.50
- AVG Volume (30 Days)
- CCM 2.7K
- SNTI 127.1K
- Earning Date
- CCM 09-26-2025
- SNTI 08-07-2025
- Dividend Yield
- CCM N/A
- SNTI N/A
- EPS Growth
- CCM N/A
- SNTI N/A
- EPS
- CCM N/A
- SNTI N/A
- Revenue
- CCM $52,603,198.00
- SNTI N/A
- Revenue This Year
- CCM N/A
- SNTI N/A
- Revenue Next Year
- CCM N/A
- SNTI $150.00
- P/E Ratio
- CCM N/A
- SNTI N/A
- Revenue Growth
- CCM N/A
- SNTI N/A
- 52 Week Low
- CCM $3.80
- SNTI $1.26
- 52 Week High
- CCM $10.77
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- CCM 55.42
- SNTI 25.49
- Support Level
- CCM $5.10
- SNTI $1.38
- Resistance Level
- CCM $5.99
- SNTI $1.47
- Average True Range (ATR)
- CCM 0.14
- SNTI 0.09
- MACD
- CCM 0.04
- SNTI -0.01
- Stochastic Oscillator
- CCM 60.67
- SNTI 10.00
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.